Sabah Öney is the founder of Dispatch Bio. Dispatch Bio has raised $216M in total funding. Latest round: Series A. Based in San Francisco, CA.
Sabah Öney is the CEO and Co-founder of Dispatch Bio, a biotechnology company founded in 2022. The company aims to develop universal immunotherapy treatments for solid tumors using CAR-T cell therapy. He leads the company after its public launch in July 2025, having raised $216 million in total funding.
Full founder directory · Investor directory · Company funding database · Fundraising library